ReviewLancet (London, England)2013
Acute lymphoblastic leukaemia.
Review in Lancet (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 527 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of New Markers for Minimal Residual Disease in Precursor B Acute Lymphoblastic Leukemia
Value of FoxO3a and PU.1 Expression in Pediatric Acute Lymphoblastic Leukemia
Who cites it
527 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,016 citations in OpenAlex.
- Pediatric-inspired regimens and HSCT for adolescents and young adults with acute lymphoblastic leukemia.Blood advances · 2026Pooled it
- Impact of body mass index at diagnosis on outcomes of pediatric acute leukemia: A systematic review and meta-analysis.PloS one · 2024Pooled it
- The incidence and mortality of childhood acute lymphoblastic leukemia in Indonesia: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis.Annals of hematology · 2021Pooled it
- Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia.Leukemia · 2023Trial
- Article
- Pathway incompatibility between NF-κB and RAS signaling constrains oncogenicity in B-cell leukemia.The Journal of biological chemistry · 2026Article
- Association of Childhood Acute Leukemia With Autoimmune Diseases.International journal of cancer · 2026Article
- Global, regional, and national epidemiology of leukemia in children from 1990 to 2021: A cross-sectional study.Medicine · 2026Article
- Article
- Obesity as a risk factor for acute lymphoblastic leukemia in individuals younger than 20 years across 204 countries and territories from 1990 to 2021: a benchmarking global analysis.Annals of medicine and surgery (2012) · 2026Article
- clinTALL: machine learning-driven multimodal subtype classification and treatment outcome prediction in pediatric T-ALL.Genome medicine · 2026Article
- Clinical outcomes in pediatric acute lymphoblastic leukemia using modified BFM-95 protocol: 10-year study in Mexico City.JNCI cancer spectrum · 2026Article
- Article
- Chemotherapy-induced oxidative injury in pediatric acute lymphoblastic leukemia: The role of N-acetylcysteine (Review).Biomedical reports · 2026Review
- Article
- Hyperleukocytosis and outcomes in pediatric B-cell acute lymphoblastic leukemia: A report from the REDIAL Consortium.medRxiv : the preprint server for health sciences · 2026Article
- An explainable meta-learned hybrid CNN-transformer model with dual attention for leukemia diagnosis from peripheral blood smears.Scientific reports · 2026Article
- Clinical Phenotypes and Glycopeptide Escalation Patterns in Pediatric Febrile Neutropenia: Associations with Short-Term Outcomes and Acute Kidney Injury RiskTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026Article
- Oxidative DNA Damage as an Integrative Marker of Redox Dysfunction Associated with Doxorubicin-Induced Cardiotoxicity in Pediatric Leukemia.Current issues in molecular biology · 2026Article
467 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Acute lymphoblastic leukaemia occurs in both children and adults but its incidence peaks between 2 and 5 years of age. Causation is multifactorial and exogenous or endogenous exposures, genetic susceptibility, and chance have roles. Survival in paediatric acute lymphoblastic leukaemia has improved to roughly 90% in trials with risk stratification by biological features of leukaemic cells and response to treatment, treatment modification based on patients' pharmacodynamics and pharmacogenomics, and improved supportive care. However, innovative approaches are needed to further improve survival while reducing adverse effects. Prognosis remains poor in infants and adults. Genome-wide profiling of germline and leukaemic cell DNA has identified novel submicroscopic structural genetic changes and sequence mutations that contribute to leukaemogenesis, define new disease subtypes, affect responsiveness to treatment, and might provide novel prognostic markers and therapeutic targets for personalised medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.